Stock CYTOSORBENTS CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Cytosorbents Corp OTC Bulletin Board

Equities

US23283X2062

Real-time Estimate Cboe BZX
Other stock markets
 15:17:26 2024-05-17 EDT
0.945 USD 0.00% Intraday chart for Cytosorbents Corp
05-09 Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M MT
05-09 Transcript : Cytosorbents Corporation, Q1 2024 Earnings Call, May 09, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CytoSorbents: Q1 Earnings Snapshot
AQ
CytoSorbents Reports First Quarter 2024 Results
GL
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
GL
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
GL
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
GL
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
GL
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
GL
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
GL
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
GL
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
PR
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
GL
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
GL
CytoSorbents: Q3 Earnings Snapshot
AQ
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTSO Stock
  4. Stock
  5. News Cytosorbents Corp
  6. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW